Emmanuel Antonarakis

Congrats @laurasenamd for publishing the definitive study on IDH1-altered prostate cancers. This is a distinct molecular subtype of PCa with novel therapeutic implications (vorasidenib?). @neerajaiims @VanAllenLab @nikolausschultz europeanurology.com/action/showPdf…

@UMNCancer @aliarafaa Congratulations to lead researcher and first author @aliarafaa

Not all patients respond to prostate cancer treatment the same way. Researchers at MCC, including @aliarafaa and @EAntonarakis, are studying how blood-based biomarkers could help guide more personalized treatment decisions. Learn more: cancer.umn.edu/news/beyond-im…

Congrats @aliarafaa and @DrJustinDrake for your elegant work on plasma extracellular vesicle (EV) proteomics in Pluvicto-treated prostate cancer patients. Blood-based detection of PSMA, B7-H3, STEAP1 and Trop2 will help precision therapeutics! @UMNCancer cell.com/cell-reports-m…

@laurasenamd Congratulations @laurasenamd A very important study

While it is becoming trendy to start tx for advanced PCa @ BCR, earlier tx can mean earlier tx-resistance. We studied PCa kinetics longitudinally to find that CRPC is associated w disease acceleration, which has potential to shorten OS of pts w early tx 🧵 onlinelibrary.wiley.com/doi/full/10.10…

Please check out our CASCARA trial, the first study to use a quadruplet initial systemic regimen for high-volume metastatic prostate cancer. Let’s design a randomized Phase 3 trial to explore this further. @charlesryanmd @UMNCancer aacrjournals.org/clincancerres/…

@MAWildgust @JNJInnovMed This will be a big step forward for drug development in prostate cancer and beyond

Excited to welcome the Halda team to @JNJInnovMed with and it’s novel platform to revolutionize cancer treatment and enable next-generation oral therapies. #MyCompany jnj.com/media-center/p…

@docmool @guptaarjun90 Congratulations, Dr Khealani !

Just published in Frontiers in Oncology — a case of gBRCA2 metastatic rectal high-grade NEC with a durable near-CR on talazoparib. Grateful to @guptaarjun90 @EAntonarakis frontiersin.org/journals/oncol… #GIOnc #NEC #BRCA2 #PARP

@DMakrakisMD @YaleHemOnc @PGrivasMDPhD @PavlosMsaouel @AndrewGutwein @SM_Esagian @pdzavras @BraunMDPhD @DanielPetrylak Συγχαρητήρια Δημήτρη. Είμαστε πολύ περήφανοι για εσένα.

Immensely excited to match at @YaleHemOnc for Fellowship! Very grateful to my mentors @PGrivasMDPhD @PavlosMsaouel R. Gralla and B. Gartrell, my PD @AndrewGutwein and ⭐️ ⭐️ @SM_Esagian @pdzavras; wouldn’t be feasible without their huge support! @BraunMDPhD @DanielPetrylak

Great talk by @ZorkoNK about B7-H3-targeting TriKEs at the DAVA Oncology meeting in Bermuda. @UMNews @UMNCancer

@LiangChengMD @EUplatinum Congrats @maughanonc

New State-of-the-Art Review: “The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies” - just published in the November issue of European Urology @EUplatinum by Dr. Benjamin Maughan and colleagues. It’s a great honor to be part of this amazing team, led by Dr.Shilpa Gupta. Liquid biopsies offer many promising areas of potential clinical utility. We believe there is now sufficient validation to justify their use in patients with genitourinary cancers. We recommend somatic tumor testing for all patients with metastatic genitourinary malignancies, given both disease-specific and disease-agnostic indications. Such testing may also provide important prognostic insights that can guide patient counseling, though certain applications still require validation in prospective, biomarker-driven clinical trials. We strongly encourage the extensive use of liquid biopsy testing when indicated, aiming to improve outcomes and support further research. The clinical utility of liquid biopsies is expected to expand further as additional indications are evaluated and validated. Future applications may include patient selection for adjuvant therapy in renal cell carcinoma and/or urothelial carcinoma, screening of high-risk populations, and new predictive assays for systemic therapy. Each new application will need to be validated in appropriately designed clinical studies as part of the ongoing effort to advance personalized medicine and improve patient outcomes. The full article is available here: sciencedirect.com/science/articl…   @maughanonc @LDyrskjot @PGrivasMDPhD @EAntonarakis @bilenma @tbivala1 @dr_coops @shilpaonc

Congrats @PornladaL for publishing the first comprehensive analysis of HLA class-I expression in prostate cancer, and the associated genomic, transcriptomic, immunologic, and clinical consequences. This will be a landmark paper in the field. nature.com/articles/s4139…

It was a sheer pleasure to have @AdamSharpMedOnc here in Minnesota delivering a Cancer Center Seminar lecture about manipulation of the apoptosis pathway for prostate cancer therapeutics. Thanks @scottdehm for inviting and hosting him. Let the collaborations begin! @UMNCancer

@neerajaiims @TheLancet @PCFnews @urotoday @OncoAlert @montypal @DrChoueiri @VivekSubbiah @umangtalking @AzadOncology @PGrivasMDPhD @TomVargheseJr @shilpaonc @APCCC_Lugano @tompowles1 Two Lancet papers in one day. Wow. I find the CDK12 result intriguing! Congrats again

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert

Largest retrospective study (N=93) of checkpoint-inhibitor efficacy in pts with dMMR mCRPC. Those with 3-4 modes of dMMR detection (protein IHC loss, gene alteration, MSI-hi, and TMB >20) have greatest survival. euoncology.europeanurology.com/action/showPdf…

A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 @neerajaiims @PCFnews @urotoday @EdEsplin nature.com/articles/s4139…

Congrats @chadihcmd for this impactful study. You are a superstar ⭐️

Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i @OncoAlert @urotoday

Congratulations @aliarafaa on developing the first prognostic blood-based PROTEOMIC biomarker for 177Lu-PSMA-617 efficacy, presented at ASCO ‘25. @UMNCancer @UMNews meetings.asco.org/abstracts-pres…

@JakeOrmeMDPhD @scottdehm Congratulations @JakeOrmeMDPhD on your beautiful editorial

Fascinating work by Chen et al in uncovering new metabolomics of SPOP-mutant prostate cancer, we review here @EAntonarakis @scottdehm nature.com/articles/s4301…